Details of the Drug Combination

General Information of Drug Combination (ID: DC4PTVZ)

Drug Combination Name
BIO-300 Pralatrexate
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Pralatrexate   DMAO80I
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: BT-549
Zero Interaction Potency (ZIP) Score: 2.5
Bliss Independence Score: 3.37
Loewe Additivity Score: 4.64
LHighest Single Agent (HSA) Score: 4.49

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Pralatrexate
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [4]
Peripheral T-cell lymphoma 2A90.C Approved [4]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [5]
Pralatrexate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Polypeptide deformylase (PDF) TT9SL3Q DEFM_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Pralatrexate Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Folate transporter 1 (SLC19A1) DTOSN46 S19A1_HUMAN Substrate [7]
Proton-coupled folate transporter (SLC46A1) DTDJEMI PCFT_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Pralatrexate Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Folylpolyglutamate synthase (FPGS) DECWT2V FOLC_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Clear cell renal cell carcinoma DC9W0AH TK-10 Investigative [9]
Glioma DCWJA87 SF-268 Investigative [9]
Renal cell carcinoma DC51QZQ SN12C Investigative [9]
Carcinoma DCEOULW RXF 393 Investigative [1]
Adenocarcinoma DC3SYXH A549 Investigative [10]
Adenocarcinoma DC5JUYU NCIH23 Investigative [10]
Adenocarcinoma DC2KZN3 HCC-2998 Investigative [10]
Adenocarcinoma DCMF0HK HCT-15 Investigative [10]
Adenocarcinoma DCUZSPM SW-620 Investigative [10]
Lung adenocarcinoma DC1R7KU HOP-62 Investigative [10]
Malignant melanoma DCY20O5 UACC62 Investigative [10]
Pleural epithelioid mesothelioma DCIG22O NCI-H226 Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6840).
5 Pralatrexate FDA Label
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.
8 Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. Expert Opin Pharmacother. 2013 Mar;14(4):515-23.
9 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
10 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.